RESUMEN

The ability of 2-deoxy-d-glucose (2-DG) to interfere with d-glucose metabolism demonstrates that nutrient and energy deprivation is an efficient tool to suppress cancer cell growth and survival. Acting as a d-glucose mimic, 2-DG inhibits glycolysis due to formation and intracellular accumulation of 2-deoxy-d-glucose-6-phosphate (2-DG6P), inhibiting the function of hexokinase and glucose-6-phosphate isomerase, and inducing cell death. In addition to glycolysis inhibition, other molecular processes are also affected by 2-DG. Attempts to improve 2-DG's drug-like properties, its role as a potential adjuvant for other chemotherapeutics, and novel 2-DG analogs as promising new anticancer agents are discussed in this review.

Asunto(s)

Desoxiglucosa/análogos & derivados , Desoxiglucosa/uso terapéutico , Glioblastoma/tratamiento farmacológico , Muerte Celular/efectos de los fármacos , Terapia Combinada , Desoxiglucosa/química , Desoxiglucosa/farmacología , Glioblastoma/diagnóstico , Glioblastoma/metabolismo , Glioblastoma/radioterapia , Glucosa/química , Glucosa/metabolismo , Glucosa-6-Fosfato/metabolismo , Glucosa-6-Fosfato Isomerasa/antagonistas & inhibidores , Glucosa-6-Fosfato Isomerasa/metabolismo , Glucólisis/efectos de los fármacos , Hexoquinasa/metabolismo , Humanos